Huang Chao, He Jun, Dong Yi, Huang Li, Chen Yichao, Peng Anquan, Huang Hao
Department of Otolaryngology-Head and Neck Surgery, Second Xiangya Hospital Central South University, Changsha, China.
Department of Nephrology, Xiangya Hospital Central South University, Changsha, China.
Front Oncol. 2022 Jan 11;11:779153. doi: 10.3389/fonc.2021.779153. eCollection 2021.
Laryngeal squamous cell carcinoma (LSCC) is a leading malignant cancer of the head and neck. Patients with LSCC, in which the cancer has infiltrated and metastasized, have a poor prognosis. Therefore, there is an urgent need to identify more potential targets for drugs and biomarkers for early diagnosis.
RNA sequence data from LSCC and patients' clinical traits were obtained from the Gene Expression Omnibus (GEO) (GSE142083) and The Cancer Genome Atlas (TCGA) database. Differentially expressed gene (DEG) analysis and weighted gene co-expression network analysis (WGCNA) were performed to identify hub genes. Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, prognostic value analysis, receiver operating characteristic (ROC) curve analysis, gene mutation analysis, tumor-infiltrating immune cell abundance profile estimation, gene set variation analysis (GSVA), and gene set enrichment analysis (GSEA) were performed. Single-gene RNA sequencing data were obtained from the GSE150321 dataset. Cell proliferation and viability were confirmed by the CCK-8 assay and real-time PCR.
A total of 701 DEGs, including 329 upregulated and 372 downregulated genes, were screened in the GSE142083 dataset. Using WGCNA, three modules were identified to be closely related to LSCC. After intersecting the DEGs and performing univariate and multivariate Cox analyses, a novel prognostic model based on three genes (, , and ) for LSCC was established. Interfering expression inhibited tumor cell proliferation and migration.
Our results show that , , and have the potential to become new therapeutic targets and prognostic biomarkers for LSCC.
喉鳞状细胞癌（LSCC）是头颈部位主要的恶性肿瘤。癌症已浸润和转移的LSCC患者预后较差。因此，迫切需要确定更多潜在的药物靶点和早期诊断的生物标志物。
从基因表达综合数据库（GEO）（GSE142083）和癌症基因组图谱（TCGA）数据库中获取LSCC的RNA序列数据和患者的临床特征。进行差异表达基因（DEG）分析和加权基因共表达网络分析（WGCNA）以鉴定枢纽基因。进行基因本体论（GO）、京都基因与基因组百科全书（KEGG）分析、预后价值分析、受试者工作特征（ROC）曲线分析、基因突变分析、肿瘤浸润免疫细胞丰度谱估计、基因集变异分析（GSVA）和基因集富集分析（GSEA）。单基因RNA测序数据来自GSE150321数据集。通过CCK-8测定和实时PCR确认细胞增殖和活力。
在GSE142083数据集中筛选出总共701个DEG，包括329个上调基因和372个下调基因。使用WGCNA，鉴定出三个与LSCC密切相关的模块。在对DEG进行交集并进行单变量和多变量Cox分析后，建立了一种基于三个基因（、和）的LSCC新型预后模型。干扰表达可抑制肿瘤细胞增殖和迁移。
我们的结果表明，、和有潜力成为LSCC的新治疗靶点和预后生物标志物。
